Abstract
Tacrine-huperzine A hybrids (huprines) are a new class of very potent and selective acetylcholinesterase (AChE) inhibitors. Huprines were designed from tacrine and (-)-huperzine A through a conjunctive approach. They combine the 4-aminoquinoline substructure of tacrine with the carbobicyclic substructure of (-)-huperzine A. Structural variations on several parts of a lead structure have allowed to complete a structure-activity relationship exploration of this new structural family and have led to several huprines more active than other known AChE inhibitors.
Keywords: Tacrine-huperzine A hybrids (huprines), acetylcholinesterase (AChE) inhibitors, tacrine, (-)-huperzine A, amyloid peptide, amyloid precursor proteine, Acetylcholinesterase, Torpedo Californica Acetylcholinesterase
Mini-Reviews in Medicinal Chemistry
Title: Tacrine-Huperzine A Hybrids (Huprines) A New Class of Highly Potent and Selective Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer Disease
Volume: 1 Issue: 2
Author(s): P. Camps and D. Munoz-Torrero
Affiliation:
Keywords: Tacrine-huperzine A hybrids (huprines), acetylcholinesterase (AChE) inhibitors, tacrine, (-)-huperzine A, amyloid peptide, amyloid precursor proteine, Acetylcholinesterase, Torpedo Californica Acetylcholinesterase
Abstract: Tacrine-huperzine A hybrids (huprines) are a new class of very potent and selective acetylcholinesterase (AChE) inhibitors. Huprines were designed from tacrine and (-)-huperzine A through a conjunctive approach. They combine the 4-aminoquinoline substructure of tacrine with the carbobicyclic substructure of (-)-huperzine A. Structural variations on several parts of a lead structure have allowed to complete a structure-activity relationship exploration of this new structural family and have led to several huprines more active than other known AChE inhibitors.
Export Options
About this article
Cite this article as:
Camps P. and Munoz-Torrero D., Tacrine-Huperzine A Hybrids (Huprines) A New Class of Highly Potent and Selective Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer Disease, Mini-Reviews in Medicinal Chemistry 2001; 1 (2) . https://dx.doi.org/10.2174/1389557013406972
DOI https://dx.doi.org/10.2174/1389557013406972 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Ornithine Decarboxylase Activity by Phenolics Based Structurally Related Compounds Synthesized on Steroidal and Non-Steroidal Skeleton and their Radical Scavenging Action
Current Bioactive Compounds Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Role of Transcranial Doppler Ultrasonography in Cerebrovascular Disease
Recent Patents on CNS Drug Discovery (Discontinued) The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Identification of Novel β3-Adrenoceptor Agonists Using Energetic Analysis, Structure Based Pharmacophores and Virtual Screening
Combinatorial Chemistry & High Throughput Screening AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Emerging Therapeutic Strategies for Rheumatoid Arthritis
Current Drug Therapy Naphthalene Toxicity in Clinical Practice
Current Drug Metabolism Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases
Current Pharmaceutical Design Binding Sites of Amyloid β-Peptide in Cell Plasma Membrane and Implications for Alzheimers Disease
Current Protein & Peptide Science Morphine Stimulates Vascular Endothelial Growth Factor-Like Signaling in Mouse Retinal Endothelial Cells
Current Neurovascular Research Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less
Infectious Disorders - Drug Targets Experimental Methods for Studying the Interactions between G-Quadruplex Structures and Ligands
Current Pharmaceutical Design Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Inhibition of Ataxia Telangiectasia-p53-E2F-1 Pathway in Neurons as a Target for the Prevention of Neuronal Apoptosis
Current Drug Metabolism Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacokinetics of Dihydroergocristine and Its Major Metabolite 8- Hydroxy-Dihydroergocristine in Human Plasma
Current Drug Metabolism